These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15953708)

  • 1. Significant increases in the levels of liver enzymes in mice treated with anti-tuberculosis drugs.
    Lenaerts AJ; Johnson CM; Marrieta KS; Gruppo V; Orme IM
    Int J Antimicrob Agents; 2005 Aug; 26(2):152-8. PubMed ID: 15953708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis.
    Byrne ST; Denkin SM; Zhang Y
    J Antimicrob Chemother; 2007 Feb; 59(2):313-6. PubMed ID: 17185297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention of resistance to rifampicin by pyrazinamide in experimental tuberculosis in the mouse].
    Grosset J; Truffot-Pernot C; Poggi S; Lecoeur H; Chastang C
    Rev Mal Respir; 1985; 2(4):205-8. PubMed ID: 3937188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrazinamide serum levels in childhood tuberculosis.
    Thee S; Detjen A; Wahn U; Magdorf K
    Int J Tuberc Lung Dis; 2008 Sep; 12(9):1099-101. PubMed ID: 18713511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period.
    Jahng AW; Tran T; Bui L; Joyner JL
    Transplantation; 2007 Jun; 83(12):1557-62. PubMed ID: 17589337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Status quo of pyrazinamide as an antituberculosis drug].
    Kameda K
    Kekkaku; 1995 Jul; 70(7):445-55. PubMed ID: 7564054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
    Pandey R; Sharma S; Khuller GK
    Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
    Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
    Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
    Matsumoto M; Hashizume H; Tomishige T; Kawasaki M; Tsubouchi H; Sasaki H; Shimokawa Y; Komatsu M
    PLoS Med; 2006 Nov; 3(11):e466. PubMed ID: 17132069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-tuberculosis chemotherapy].
    Wada M
    Kekkaku; 2007 Oct; 82(10):771-81. PubMed ID: 18018601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis.
    Hu Y; Coates AR; Mitchison DA
    Int J Tuberc Lung Dis; 2006 Mar; 10(3):317-22. PubMed ID: 16562713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2001 Aug; 50(34):733-5. PubMed ID: 11787580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifampicin/pyrazinamide therapy should not be used for latent tuberculosis infection.
    Garca-Doval I
    J Am Acad Dermatol; 2004 May; 50(5):801; author reply 801-2. PubMed ID: 15097974
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles.
    Ahmad Z; Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2008 Feb; 31(2):142-6. PubMed ID: 18155883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New approaches to the treatment of latent tuberculosis.
    Sterling TR
    Semin Respir Crit Care Med; 2008 Oct; 29(5):532-41. PubMed ID: 18810686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses.
    Ahmad Z; Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2006 May; 27(5):409-16. PubMed ID: 16624533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis.
    Ahmad Z; Sharma S; Khuller GK
    FEMS Microbiol Lett; 2006 Aug; 261(2):181-6. PubMed ID: 16907718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.